-
New ACT EU video releasedClinical Trials |Regulatory
New ACT EU video released
-
New ACT EU video releasedClinical Trials |Regulatory
New ACT EU video released
Watch a video to learn about how the Accelerating Clinical Trials in the EU (ACT EU) initiative is transforming the way clinical trials are initiated, designed, and run
-
CHMP highlights: September 2023MEDICINES |COMMITTEES
CHMP highlights: September 2023
-
CHMP highlights: September 2023MEDICINES |COMMITTEES
CHMP highlights: September 2023
EMA's human medicines committee (CHMP) recommended nine new medicines for approval in the EU at its September 2023 meeting.
-
EMA cooperation with HTA bodies in the EUHTA Regulation |EUnetHTA
EMA cooperation with HTA bodies in the EU
-
EMA cooperation with HTA bodies in the EUHTA Regulation |EUnetHTA
EMA cooperation with HTA bodies in the EU
The EMA-EUnetHTA cooperation is coming to an end, but preparations are continuing for the implementation of the regulation on health technology assessment.
-
Approval of adapted Spikevax COVID-19 vaccineCOVID-19 |Vaccines
Approval of adapted Spikevax COVID-19 vaccine
-
Approval of adapted Spikevax COVID-19 vaccineCOVID-19 |Vaccines
Approval of adapted Spikevax COVID-19 vaccine
Adapted Spikevax COVID-19 vaccine targets the Omicron XBB.1.5 subvariant
Latest news
-
List item15/09/2023
Towards a permanent collaboration framework for EMA and Health Technology Assessment bodies
Over the past three years, EMA and the EUnetHTA 21 (European Network for Health Technology Assessment) consortium have delivered a number of milestones to prepare the EU for the entry into application of the Regulation on Health Technology...
-
List item15/09/2023
EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep
EMA’s human medicines committee (CHMP) has recommended not renewing the conditional marketing authorisation for Blenrep (belantamab mafodotin), a medicine used to treat multiple myeloma (a cancer of the bone marrow). Blenrep is given to adults who...
-
List item15/09/2023 COVID-19
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023
Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its September 2023 meeting. The CHMP recommended granting a marketing authorisation for Ebglyss (lebrikizumab), for the...
-
List item15/09/2023
EMA recommends non-renewal of authorisation of Duchenne muscular dystrophy medicine Translarna
EMA’s human medicines committee (CHMP) has recommended not renewing the marketing authorisation for Translarna (ataluren), a medicine for treating patients with Duchenne muscular dystrophy whose disease is caused by a type of genetic defect called a...
-
List item14/09/2023 COVID-19
Spikevax: EMA recommends approval of adapted COVID-19 vaccine targeting Omicron XBB.1.5
EMA’s human medicines committee (CHMP) has recommended authorising an adapted Spikevax vaccine targeting the Omicron XBB.1.5 subvariant. The vaccine — known as Spikevax XBB.1.5 — is to be used for preventing COVID-19 in adults and children from 6...
-
List item08/09/2023
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 5-7 September 2023
CVMP opinions on veterinary medicinal products Under Regulation (EC) No 726/2004, the Committee adopted by consensus a positive opinion for a marketing authorisation application for Oxmax ( hemoglobin betafumaril (bovine) ), from New Alpha...
Information for you






Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal